A team of researchers has discovered that changes in speed of electrical signals across the optic nerves may reflect recovery of the myelin loss during multiple sclerosis.
Having previously been demonstrated to allow dopamine replenishment, results of a recent clinical trial suggest nilotinib could be a safe and well-tolerated treatment for individuals with Parkinson’s disease.
A mouse study has demonstrated that glioblastoma could be treated directly using an ultrasound technique that delivers a potent treatment across the blood–brain barrier into the tumor.
A common mutation in a key enzyme involved in alcohol metabolism may increase damage in cells obtained from individuals with Alzheimer’s disease and in mice.
A team of researchers discovered how amyloid-β and tau proteins work together to disrupt cell communication in the brains of individuals with Alzheimer’s disease.
Researchers have determined the electrode placement during deep brain stimulation needs to be tailored to the patient as the locations of functional brain networks vary on an individual basis.
At the Clinical Trials on Alzheimer’s Disease Congress this week, Biogen (MA, USA) has provided a detailed report on the latest aducanumab results, including why there was such a difference in the results between ENGAGE and EMERGE.
A recent set of studies reports how blood–brain barrier leakage may affect inflammation in the brain, potentially leading to acceleration of neurological aging in mice.
Artificial neurons have been developed in a first-of-its-kind achievement that closely resemble biological neurons, mimicking their responses to a range of stimulations.
Researchers have discovered a correlation between reaction time and white matter microstructure damage in patients with concussion, suggesting an alteration in signaling patterns as a result of mild traumatic brain injury.